2023
OUTC-08. IMPLEMENTING SOCIAL DETERMINANT OF HEALTH DATA COLLECTION FOR PEDIATRIC, ADOLESCENT AND YOUNG ADULT NEURO-ONCOLOGY PATIENTS IN THE CLINICAL TRIAL CONSORTIA SETTING: PROGRESS AND CHALLENGES
Puthenpura V, Bona K, Cooney T, Coven S, Davidson T, Fouladi M, Kline C, Leary S, Mueller S, Green A, Marks A. OUTC-08. IMPLEMENTING SOCIAL DETERMINANT OF HEALTH DATA COLLECTION FOR PEDIATRIC, ADOLESCENT AND YOUNG ADULT NEURO-ONCOLOGY PATIENTS IN THE CLINICAL TRIAL CONSORTIA SETTING: PROGRESS AND CHALLENGES. Neuro-Oncology 2023, 25: i37-i37. PMCID: PMC10260067, DOI: 10.1093/neuonc/noad073.145.Peer-Reviewed Original ResearchNeuro-oncology patientsMulticenter clinical trialClinical trialsSocial determinantsSocioeconomic statusClinical Trials ConsortiumLong-term complicationsAYA cancer patientsAdverse social determinantsSocioeconomic status dataAdverse SDOHSurvival disparitiesMultidisciplinary careTherapy adherenceToxicity incidenceCancer patientsTrial therapyPersonal socioeconomic statusOutcome disparitiesTrial designSDOHPatientsHealth equityHealth data collectionTrials
2021
CLRM-03. BGB-290 AND TEMOZOLOMIDE IN TREATING ISOCITRATE DEHYDROGENASE (IDH)1/2-MUTANT GRADE I-IV GLIOMAS – A NOVEL MODEL OF AYA TRIAL DEVELOPMENT AND DEPLOYMENT
Marks A, Bindra R. CLRM-03. BGB-290 AND TEMOZOLOMIDE IN TREATING ISOCITRATE DEHYDROGENASE (IDH)1/2-MUTANT GRADE I-IV GLIOMAS – A NOVEL MODEL OF AYA TRIAL DEVELOPMENT AND DEPLOYMENT. Neuro-Oncology Advances 2021, 3: iv1-iv1. PMCID: PMC8453774, DOI: 10.1093/noajnl/vdab112.002.Peer-Reviewed Original ResearchAdult Brain Tumor ConsortiumAYA populationAYA patientsClinical trialsIDH1/2 mutationsPatients ages 13Years of ageInternational clinical trialsYoung adult populationTemozolomide chemotherapyInitial dosingLack of enrollmentGrade IPsychosocial assessmentPARP inhibitor sensitivityUnique cohortDisease processMost trialsGlioma populationInternational trialTrial developmentAdult populationSpecific trialsPatientsTrials